#

GNVPN.019BUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of		Group Art Unit: 1632
James M. Wilson et al)) Examiner: J. Martin
Appln	No. 09/242,977))
Filed:	February 26, 1999))
For:	METHOD FOR RECOMBINANT ADENO-ASSOCIATED VIRUS DIRECTED GENE THERAPY)) January 24, 2000))

Assistant Commissioner for Patents Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

The following documents are submitted to the Examiner, pursuant to 37 CFR §§1.56 and 1.97. Form PTO-1449 is attached and copies of the references are enclosed herewith. This Supplemental Information Disclosure Statement is submitted more than three months from the filing date of this application, but prior to receipt of an Office Action on the merits. Therefore, no fees or declarations are believed due. However, the Commissioner is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our deposit account number 08-3040.

U. S. PATENTS

(AJ)	U. S. Patent No. 5,789,390, issued August 4, 1998
(AK)	U. S. Patent No. 5,116,739, issued May 26, 1992

(AAA) U. S. Patent No. 5,672,685, issued September 30, 1997

PUBLISHED FOREIGN PATENT APPLICATIONS

(BBP) International Patent Application No. WO96/14837, published May 23, 1996

REMARKS

The Examiner is respectfully requested to consider the enclosed documents during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for the Applicants

Bv

Cathy & Kodis

Registration No. 33,980

Spring House Corporate Center

Box 457

Spring House, PA 19477

Telephone: (215) 540-9210

Telefacsimile: (215) 540-5818